Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 3
2020 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells.
Dillard C, Kiyohara M, Mah V, McDermott SP, Bazzoun D, Tsui J, Chan AM, Haddad G, Pellegrini M, Chang YL, Elshimali Y, Wu Y, Vadgama JV, Kim SR, Goodglick L, Law SM, Patel DD, Dhawan P, O'Brien NA, Gordon LK, Braun J, Lazar G, Wicha MS, Wadehra M. Dillard C, et al. Among authors: kiyohara m. Mol Cancer Ther. 2020 Aug;19(8):1682-1695. doi: 10.1158/1535-7163.MCT-19-0850. Epub 2020 May 25. Mol Cancer Ther. 2020. PMID: 32451329 Free PMC article.
Epithelial membrane protein-2 (EMP2) activates Src protein and is a novel therapeutic target for glioblastoma.
Qin Y, Fu M, Takahashi M, Iwanami A, Kuga D, Rao RG, Sudhakar D, Huang T, Kiyohara M, Torres K, Dillard C, Inagaki A, Kasahara N, Goodglick L, Braun J, Mischel PS, Gordon LK, Wadehra M. Qin Y, et al. Among authors: kiyohara m. J Biol Chem. 2014 May 16;289(20):13974-85. doi: 10.1074/jbc.M113.543728. Epub 2014 Mar 18. J Biol Chem. 2014. PMID: 24644285 Free PMC article.
EMP2 Serves as a Functional Biomarker for Chemotherapy-Resistant Triple-Negative Breast Cancer.
Chan AM, Aguirre B, Liu L, Mah V, Balko JM, Tsui J, Wadehra NP, Moatamed NA, Khoshchehreh M, Dillard CM, Kiyohara M, Elshimali Y, Chang HR, Marquez-Garban D, Hamilton N, Pietras RJ, Gordon LK, Wadehra M. Chan AM, et al. Among authors: kiyohara m. Cancers (Basel). 2024 Apr 12;16(8):1481. doi: 10.3390/cancers16081481. Cancers (Basel). 2024. PMID: 38672563 Free PMC article.
Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer.
Fu M, Maresh EL, Helguera GF, Kiyohara M, Qin Y, Ashki N, Daniels-Wells TR, Aziz N, Gordon LK, Braun J, Elshimali Y, Soslow RA, Penichet ML, Goodglick L, Wadehra M. Fu M, et al. Among authors: kiyohara m. Mol Cancer Ther. 2014 Apr;13(4):902-15. doi: 10.1158/1535-7163.MCT-13-0199. Epub 2014 Jan 21. Mol Cancer Ther. 2014. PMID: 24448822 Free PMC article.